Wegovy 2 Week Results: What Most People Notice First

Step 1, What the 0.25 mg starting dose is actually doing at week two

You inject your first Wegovy dose at 0.25 mg. Two weeks later, you are still at exactly that level. It is worth being honest about what this dose is for: it is not your treatment dose. Its job is to let your digestive system and appetite regulation adapt before the medicine steps up to 0.5 mg, then 1.0 mg, 1.7 mg and eventually 2.4 mg, the maintenance dose where most of the trial results were measured. Semaglutide, the active ingredient in Wegovy, works by activating GLP-1 receptors that slow gastric emptying and signal fullness to the brain. Even at 0.25 mg that process has begun; you just have not yet reached the level where its effect on body weight becomes substantial.

The practical upshot: if you weigh yourself at day fourteen and see little change, that is not a sign the medicine is not working. Your prescriber and the timeline of how long Wegovy takes to work both reflect the same reality, this is a months-long process. One question our prescribers hear most weeks is "should I already feel different?" The honest answer is: possibly a little, and that is enough for now.

The week one picture is similar, mainly your body registering a new signal, not a new number on the scales. Week two adds a second injection, which some people find brings the first noticeable nudge in hunger.

Step 2, The appetite changes that tend to arrive before the weight does

The most consistent early reports from people starting Wegovy are appetite-related rather than weight-related. A meal that would normally leave room for more starts to feel complete sooner. The background noise of hunger between meals becomes quieter. Food cravings, particularly for high-calorie foods, may feel less urgent. None of this is dramatic at week two, but it is the mechanism doing its job.

This matters because it reframes what "results" means in the first fortnight. The scales measure one output. Your appetite is another, and it tends to shift first. That shift, maintained and built upon through the titration schedule, is what drives the average reductions seen in longer-term evidence. The STEP 1 trial, published in the New England Journal of Medicine, followed participants over 68 weeks and recorded an average body-weight reduction of around 15% at the 2.4 mg maintenance dose, but those gains accumulated over many months of gradually increasing doses, not the first two weeks.

If you are finding week two difficult (managing nausea, adjusting to the injection routine, wondering whether this is right for you) that is an understandable place to be. Most people who continue past the first month report that the early discomfort eases considerably.

Step 3, Side effects to expect (and what they usually mean)

The first two weeks are when gastrointestinal effects are most likely to show up. Nausea is the most commonly reported, followed by constipation, loose stools, indigestion and burping. These are dose-dependent effects: because 0.25 mg is the lowest step, most people find them mild at this stage. They tend to ease as the body adjusts, usually within days to two weeks.

Eating smaller portions, avoiding fatty or spicy foods and staying well hydrated all help. Your prescriber or pharmacist can advise on managing specific symptoms, and the NHS semaglutide medicines page lists what to watch for and when to seek medical help. Severe, persistent stomach pain that spreads to your back is one symptom that warrants prompt medical attention rather than waiting it out.

Injection-site reactions (mild redness or irritation) are also common early on and generally settle. Rotating the site each week (abdomen, thigh or upper arm) reduces localised discomfort. For a broader sense of how things typically progress from here, the week three picture is a useful next reference point.

What week two results actually tell you about your journey

Two weeks in, the most useful signal is not weight lost, it is whether you are tolerating the medicine and noticing even small changes in appetite or eating behaviour. Both point in the right direction. The prescribers and clinical team at nume look at the full pattern across months, not the fortnight score.

For context on how results typically develop as the dose increases, the six-week point and eight-week mark often show more visible progress as titration continues. The four-week stage, when most people move to 0.5 mg, is typically where appetite changes feel more pronounced.

Wegovy is a prescription-only medicine and the right dose, pace of titration and ongoing support are decisions made with a clinician. If you are considering starting treatment, a cost overview and details about what to expect from private treatment are available, and when you are ready to take the first step, you can start a free consultation with our prescribers, who review every application the same day.